2017
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discovery 2017, 7: cd-17-0593. PMID: 29025772, PMCID: PMC5718941, DOI: 10.1158/2159-8290.cd-17-0593.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsPatient-derived xenograftsHLA class ILung cancerClass ICell surface HLA class ILung cancer mouse modelPD-1 blockadeStandard treatment algorithmCancer mouse modelLung cancer samplesDefective antigen processingCheckpoint inhibitorsPD-1Treatment algorithmMouse modelAntagonistic antibodiesDiverse malignanciesAntigen processingCancer samplesB2MHomozygous lossTumorsCancerRecurrent mutations
2008
Molecular Classification of HPV‐Associated Head Neck Cancer
Weinberger P, Yu Z, Kountourakis P, Sasaki C, Kowalski D, Rimm D, Camp R, Amanda P. Molecular Classification of HPV‐Associated Head Neck Cancer. Otolaryngology 2008, 139: p91-p91. DOI: 10.1016/j.otohns.2008.05.497.Peer-Reviewed Original ResearchHPV DNA presenceClass II tumorsII tumorsClass IP16 expressionDNA presenceNeck squamous cell carcinomaHPV-specific therapiesHuman papillomavirus presenceSquamous cell carcinomaHead neck cancerP16 expression statusDistinct molecular phenotypesPatient selectionCell carcinomaNeck cancerExpression statusTumor progressionTumorsClass IIIMethods ParaffinClass IIMolecular classificationSpearman correlationDistinct subgroups